Bank of New York Mellon Corp Buys 9,639 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE)

Bank of New York Mellon Corp raised its position in Pulse Biosciences, Inc. (NASDAQ:PLSE) by 23.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 50,914 shares of the company’s stock after acquiring an additional 9,639 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.08% of Pulse Biosciences worth $570,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in shares of Pulse Biosciences by 63.6% in the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after buying an additional 2,952 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Pulse Biosciences during the 1st quarter valued at $88,000. Cetera Advisors LLC purchased a new stake in shares of Pulse Biosciences in the 1st quarter worth $109,000. PNC Financial Services Group Inc. bought a new position in Pulse Biosciences in the 4th quarter worth $242,000. Finally, Inspire Investing LLC lifted its position in Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after purchasing an additional 10,039 shares in the last quarter. 76.95% of the stock is owned by hedge funds and other institutional investors.

Pulse Biosciences Trading Down 3.1 %

NASDAQ PLSE opened at $17.32 on Tuesday. The stock has a market cap of $956.50 million, a price-to-earnings ratio of -21.38 and a beta of 1.75. Pulse Biosciences, Inc. has a 12 month low of $3.78 and a 12 month high of $22.69. The company’s 50 day moving average is $17.58 and its two-hundred day moving average is $12.70.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research report on Friday.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.